Faculty

Nadine Norton, Ph.D.

Clinical Studies

Biomarkers to Predict Cancer Therapy-related Cardiotoxicity Jacksonville, Fla., Scottsdale/Phoenix, Ariz.
The primary purpose of this study is to collect Biospecimens from patients who developed chemotherapy related cardiac toxicity (CRCT) and patients who are at a high risk for developing CRCT identified prior to the onset of therapy.
Characterization of TRPC6 to Predict and Prevent Chemotherapy Related Cardiomyopathy and Heart Failure (Prospective Study) (TRPC6) Jacksonville, Fla.
The purpose of this study is to characterize TRPC6 risk variants for doxorubicin-related cardiotoxicity in prospectively collected samples from breast cancer patients.

Breast cancer patients are more than three times at risk for developing congestive heart failure (CHF), compared with patients who did not have cancer. The increased risk of HF is observed as early as one year from diagnosis of cancer and overall, 7% of patients develop CHF (median follow-up 8.5 years)
Using induced-pluripotent stem cells to model cancer therapy-related adverse events Jacksonville, Fla.
The purpose of this study is to use patient blood cells to perform individualized in vitro modeling of cancer therapy-related toxicities.

Biomarkers to Predict Cancer Therapy-related Cardiotoxicity Rochester, Minn.
The primary purpose of this study is to collect Biospecimens from patients who developed chemotherapy related cardiac toxicity (CRCT) and patients who are at a high risk for developing CRCT identified prior to the onset of therapy.